Want to see JP:4592 full AI Analyst Report?
4592 Stock Chart & Stats
¥998.00
¥9.00(0.94%)
At close: 4:00 PM EDT
¥998.00
¥9.00(0.94%)
Day’s Range― - ―
52-Week Range¥858.00 - ¥3,990.00
Previous CloseN/A
Volume557.50K
Average Volume (3M)826.13K
Market Cap
¥74.00B
Enterprise Value¥60.11K
Total Cash (Recent Filing)¥14.00B
Total Debt (Recent Filing)¥1.18B
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Dec 10, 2026EPS Estimate
-11.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.94
Shares Outstanding78,058,880
10 Day Avg. Volume836,290
30 Day Avg. Volume826,130
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,450.00Price Target Upside45.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-49.67
Revenue Forecast (FY)¥2.15B
Bulls Say, Bears Say
Bulls Say
Improved Balance-sheet CapacityThe sharp increase in equity and generally manageable recent leverage provide a stronger solvency base for continued development activity. Although profitability is absent, this balance-sheet improvement can support operations and reduce immediate financial strain over the next several quarters.
Proprietary Regenerative-medicine PlatformA proprietary donor-derived cell-therapy platform gives SanBio a defined technological base and the potential to address significant neurological disorders. Progress across related indications could create platform leverage, allowing development capabilities and clinical knowledge to support more than one opportunity.
Losses Narrowed From The TroughThe reduction in losses from the 2023 trough is a modest but constructive operating trend. If maintained alongside continued clinical and regulatory progress, lower losses could extend financial runway and reduce the pace of capital required before a commercial earnings base is established.
Bears Say
No Established Revenue BasePersistent zero revenue means SanBio has not yet demonstrated commercial product demand or recurring operating income. The company therefore remains dependent on successful development and eventual approval of its therapies, making future earnings highly uncertain over the medium term.
Sustained Cash BurnRepeatedly negative operating and free cash flow show that ongoing activities consume substantial cash rather than funding themselves. Continued burn can shorten the available funding runway and force management to prioritize financing needs alongside research, clinical, and regulatory investment.
Dependence On External FundingReliance on external funding creates dilution and refinancing risk because the company lacks operating profits and recurring revenue to finance development internally. A rising debt balance can further constrain capital allocation and increase vulnerability if funding conditions become less favorable.
SanBio Co News
4592 FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was ¥858.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is ¥74.00B.
When is SanBio Co Ltd’s upcoming earnings report date?
SanBio Co Ltd’s upcoming earnings report date is Dec 10, 2026 which is in 77 days.
How were SanBio Co Ltd’s earnings last quarter?
SanBio Co Ltd released its earnings results on Sep 14, 2026. The company reported -¥12.24 earnings per share for the quarter, missing the consensus estimate of -¥4.797 by -¥7.443.
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Undervalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate is -11.06.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,058,880 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
SanBio Co Ltd reported an EPS of -¥12.24 in its last earnings report, missing expectations of -¥4.797. Following the earnings report the stock price went up 2.82%.
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
4592 Stock 12 Month Forecast
Average Price Target
¥1,450.00
▲(45.29% Upside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―